Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
182.08
+3.91 (2.19%)
At close: Jun 26, 2026, 4:00 PM EDT
182.85
+0.77 (0.42%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
883
Market Cap
38.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.92B |
| BeOne Medicines AG | 5.70B |
| Incyte | 5.36B |
| argenx SE | 4.74B |
| Alnylam Pharmaceuticals | 4.29B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
| Moderna | 2.23B |
RVMD News
- 3 days ago - Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 - GlobeNewsWire
- 4 days ago - Revolution Medicines begins treating patients in RASolute 305 trial - TheFly
- 5 days ago - Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. - GlobeNewsWire
- 19 days ago - RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position - TheFly
- 19 days ago - Tango Therapeutics announces data from study of vopimetostat, daraxonrasib - TheFly
- 25 days ago - Revolution Medicines price target raised to $182 from $165 at RBC Capital - TheFly
- 26 days ago - Wedbush reiterates Outperform on Revolution Medicines after ASCO data - TheFly
- 26 days ago - Revolution Medicines price target raised to $195 from $169 at H.C. Wainwright - TheFly